The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

A West Annapolis family has turned two life-altering diagnoses into more than $1 million for research toward finding a cure ...

Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial ...

"I was so angry, but I'm kind of resigned to it now." Mrs Cook said being a full-time carer has a profound impact on her ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

Ataxia Treatment Market, trends, and advancements in neurological disorder treatments. Discover growth drivers, key players, and forecasts up to 2035 ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

This valuable investigation provides new and solid evidence for a specific cognitive deficit in cerebellar degeneration patients. The authors use three tasks that modulate complexity and error ...

Researchers at the University of California-Davis have discovered a new genetic disease after studying 12 Quarter Horse foals ...

Lexeo Therapeutics (LXEO) announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia ...